Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 871 AL 885

A new biomarker classification system for AD, independent of cognition: Agnosticism is a start

Murray AD.

Neurology. 2016 Aug 2;87(5):456-7. doi: 10.1212/WNL.0000000000002931. Epub 2016 Jul 1.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.

Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1.

Retinal nerve fibre layer thickness changes in Alzheimer's disease: Results from a 12-month prospective case series

Trebbastoni A, D'Antonio F, Bruscolini A, Marcelli M, Cecere M, Campanelli A, Imbriano L, de Lena C, Gharbiya M.

Neurosci Lett. 2016 Aug 26;629:165-170. doi: 10.1016/j.neulet.2016.07.006. Epub 2016 Jul 6.

The Need for Early Detection and Treatment in Alzheimer's Disease

EBioMedicine. 2016 Jul;9:1-2. doi: 10.1016/j.ebiom.2016.07.001. Epub 2016 Jul 5.

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow

Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, Olde Rikkert M, Abdullah L, Wallin A, Walsh C, Coen R, Kenny RA, Daly L, Segurado R, Borjesson-Hanson A, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Molloy W, Tsolaki M, Howard R, Adams J, Gaynor S, Lawlor B.

BMJ Open. 2016 Jul 19;6(7):e011584. doi: 10.1136/bmjopen-2016-011584.

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease

Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ.

J Alzheimers Dis. 2016 Jul 22;54(1):223-32. doi: 10.3233/JAD-160544.

Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers

Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O' Hara R, Ashford JW, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016 Jul 25;54(1):99-107. doi: 10.3233/JAD-160413.

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Vijayan M, Reddy PH.

Biochim Biophys Acta. 2016 Oct;1862(10):1984-93. doi: 10.1016/j.bbadis.2016.08.003. Epub 2016 Aug 5.

Alzheimer's disease: presence and role of microRNAs

Basavaraju M, de Lencastre A.

Biomol Concepts. 2016 Aug 1;7(4):241-52. doi: 10.1515/bmc-2016-0014.

Applied multimodal diagnostics in a case of presenile dementia

Schönecker S, Brendel M, Huber M, Vollmar C, Huppertz HJ, Teipel S, Okamura N, Levin J, Rominger A, Danek A.

BMC Neurol. 2016 Aug 9;16:131. doi: 10.1186/s12883-016-0647-7.

Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

Ruan Q, D'Onofrio G, Sancarlo D, Greco A, Yu Z.

Mol Med Rep. 2016 Oct;14(4):3184-98. doi: 10.3892/mmr.2016.5618. Epub 2016 Aug 9.

A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease

Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R.

J Mol Neurosci. 2016 Nov;60(3):354-361. doi: 10.1007/s12031-016-0810-z. Epub 2016 Aug 11.

Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort

Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, Muck S, Scherbaum N, Wiltfang J.

J Alzheimers Dis. 2016 Sep 6;54(2):691-705. doi: 10.3233/JAD-160398.

Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels

Kuruppu S, Rajapakse NW, Spicer AJ, Parkington HC, Smith AI.

J Alzheimers Dis. 2016 Oct 4;54(3):891-895. doi: 10.3233/JAD-160492.

Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies

Pardridge WM.

Expert Opin Biol Ther. 2016 Dec;16(12):1455-1468. doi: 10.1080/14712598.2016.1230195. Epub 2016 Sep 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias